Prostate brachytherapy followed by secondary urethral adenocarcinoma: A case report.

Daniel M Callahan, Hayes W Miller, Ryan L Frazier, E Charles Osterberg, Aaron A Laviana

Abstract readCase Reports

In one paragraph

Article in Urology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Daniel M CallahanDell Medical School at the University of Texas at Austin, USA.

Hayes W MillerDell Medical School at the University of Texas at Austin, USA.

Ryan L FrazierDepartment of Surgery and Perioperative Care, Dell Medical School, USA.

E Charles OsterbergUrology Austin, USA.

Aaron A LavianaDepartment of Surgery and Perioperative Care, Dell Medical School, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate brachytherapy carries a risk of secondary malignancies, with data regarding secondary urethral malignancies being particularly sparse. We report a case of secondary urethral adenocarcinoma presenting 14 years after low-dose-rate (LDR) brachytherapy. A 57-year-old man developed recurrent urethral stenosis after LDR brachytherapy for prostate cancer (2009). In 2023, subsequent resections confirmed HER2-positive, ERBB2-amplified urethral adenocarcinoma. After neoadjuvant oxaliplatin/capecitabine (CAPOX) therapy, he underwent cystoprostatectomy, urethrectomy, and ileal conduit. Pathology showed stage IIIB disease with negative margins. This case underscores a rare but severe complication of prostate brachytherapy, contributing to the clinical understanding of secondary urethral malignancies.

Indexed as

HER2 amplificationProstate brachytherapyRadiation-induced cancerSecondary malignancyUrethral adenocarcinomaUrethral stricture

Identifiers

PMID42256662

DOI10.1016/j.eucr.2026.103495

PMCPMC13241662

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.